Investigating the Prognostic Role of Brain MRI in Anti-LGI1 Encephalitis
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Hospices Civils de Lyon
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Cognitive dysfunction and disability
Study Overview
Brief Summary
The term "autoimmune encephalitis" denotes an heterogenous group of diseases commonly associated with autoantibodies targeting neural or glial antigens. Patients harboring antibodies against the leucine-rich glioma-inactivated protein 1 (LGI1) usually respond well to immunotherapy, but a significant percentage develop cognitive sequelae and disability nonetheless. These patients would likely benefit for more aggressive and prolonged immunotherapy, aiming to prevent permanent neurological deficits. Identifying features predicting poor outcome would be crucial to guide treatment decisions. Brain magnetic resonance imaging is a key diagnostic tool in the acute phase, but radiological changes may also appear in follow-up studies, including global brain atrophy, hippocampal atrophy and mesial temporal sclerosis. We hypothesize that specific changes identifiable in the acute and chronic phase underlie a higher risk of poor outcome and persistent neurological deficits.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •- Patients with a definite diagnosis of LGI1-antibody-associated encephalitis
- •available MRI records
- •Ascertained positivity for LGI1-antibodies in serum and/or CSF
Exclusion Criteria
- •- Positivity for another antibody against neural or glial antigens
- •MRI images not available
- •Not enough clinical data to ascertain outcome
Outcomes
Primary Outcomes
Cognitive dysfunction and disability
Time Frame: 12 months
Main outcome measures will include cognitive dysfunction measured by appropriate neuropsychological evaluations, and psychiatric symptoms; it will be "none", "light", "moderate", "severe"
Secondary Outcomes
No secondary outcomes reported